12060

Compliance, persistence, and preference outcomesof postmenopausal osteoporotic women receivinga flexible or fixed regimen of daily risedronate:A multicenter, prospective, parallel group study

Objective: The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1). Methods: The study included 448 patients with postmenopausal OP. Patients were randomly assigned into six treatment groups each with a permutation of the treatment sequence (ABC, BCA, etc.) in the crossover phase (3x1 week) and randomized to 23 weeks of either the daily flexible (either regimen A, B or C) or fixed timing (only regimen A, B, or C) in the patient's preference phase. Urinary NTX-1 was tested.Results: A total of 433 patients participated in the patient's preference phase (49.7% preferred flexible and 50.3% fixed timing). There was no significant difference between the proportion of responders who were both compliant and persistent in the flexible (54.4%) and fixed regimens (53.7%) (p=0.8803). A significant difference between the flexible and fixed regimens was seen in persistence in favor of the flexible regimen (p=0.0306). There was no significant difference between the flexible and fixed regimens in terms of compliance (p=0.4611). Change in urinary NTX-1 did not show any difference between the two regimens. At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440).Conclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP

___

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medica- tion nonadherence. Value Health 2011;14:571-81.

Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treat- ment of osteoporosis increases fracture risk: systematic re- view and meta-analysis. Osteoporos Int 2010;21:1943-51.

Silverman SL, Schousboe JT, Gold DT. Oral bisphospho- nate compliance and persistence: a matter of choice? Osteo- poros Int 2011;22:21-6.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A sys- tematic review of persistence and compliance with bisphos- phonates for osteoporosis. Osteoporos Int 2007;18:1023- 31.

International Osteoporosis Foundation. The adherence gap: Why osteoporosis patients don't continue with treatment; 2005 [cited 2011 October 17]. Available from: http:// www.iofbonehealth.org/publications/the-adherence-gap. html.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Rob- inson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523.

Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011;40:275-84. e1-2.

Reginster JY. Antifracture efficacy of currently avail- able therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.

Gates BJ, Das S. Risedronate's Role in Reducing Hip Frac- ture in Postmenopausal Women with Established Osteo- porosis. Clin Med Insights Arthritis Musculoskelet Disord 2012;5:1-14.

Zhong ZM, Chen JT. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled tri- als. Clin Drug Investig 2009;29:349-57.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christian- sen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997;7:488-95.

Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopaus- al population: two years of treatment plus one year of follow- up. J Clin Endocrinol Metab 1998;83:396-402.

Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, et al. Comparison of change in bone re- sorption and bone mineral density with once-weekly alen- dronate and daily risedronate: a randomised, placebo-con- trolled study. Curr Med Res Opin 2003;19:383-94.

Agrawal S, Krueger DC, Engelke JA, Nest LJ, Krause PF, Drinka PJ, et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006;54:790-5.

Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 2009;20:1895-902.

Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.

Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, et al. Comparison of the effects of once- monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, random- ized, double-blind, active-controlled, dose-ranging study. Clin Ther 2009;31:272-85.

Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compli- ance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8.

Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteo- poros Int 2006;17:1645-52.

Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-7.

Höer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Pa- tient Prefer Adherence 2009;3:25-30.

Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteopo- rosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 2011;17:25-39.

Cramer JA, Amonkar MM, Hebborn A, Altman R. Com- pliance and persistence with bisphosphonate dosing regi- mens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60.

Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-42.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of frac- tures in osteoporotic women treated with oral bisphospho- nates. Osteoporos Int 2012;23:223-31.

Landfeldt E, Ström O, Robbins S, Borgström F. Adher- ence to treatment of primary osteoporosis and its associa- tion to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 2012;23:433-43.

Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteo- porosis--a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011;22:1537-46.

Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Re- search Database. Menopause 2012;19:33-40.

Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011;26:3-11.

Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmeno- pausal women in clinical practice versus randomized con- trolled trials. Osteoporos Int 2010;21:679-88.

Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:1296-304.

Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB. Bone turnover markers and bone mineral den- sity response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011;26:1662-9.

Silverman SL, Nasser K, Nattrass S, Drinkwater B. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a commu- nity setting-based trial. Osteoporos Int 2012;23:1069-74.

Mitchell DY, Heise MA, Pallone KA, Clay ME, Nesbitt JD, Russell DA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999;48:536-42.

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, et al. Treatment satisfaction and per- sistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US(TM). Os- teoporos Int 2012;23:733-41.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ol- lendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7.

Solomon DH, Brookhart MA, Tsao P, Sundaresan D, An- drade SE, Mazor K, et al. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int 2011;22:1737-43.

Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than fre- quency of dosing of anti-osteoporosis treatments in deter- mining patient adherence: a critical review of published ar- ticles from 1970 to 2009. Osteoporos Int 2011;22:741-53.